Hikma Searches For Strategic ‘Fourth Leg’
Considering Deals For Specialty Or Biologic Injectables
To secure long-term growth, Hikma CEO Siggi Olafsson is seeking to add a fourth strategic pillar to its global generic Injectables, US non-injectable Generics and Middle East and North Africa Branded business segments.
You may also be interested in...
Hikma CEO Siggi Olafsson says the firm is in a position to execute a major deal if the right opportunity comes along, but is not under any pressure to pursue M&A for its own sake.
Having enjoyed some success in the Middle East and North Africa region with its Remsima infliximab biosimilar for autoimmune disorders, Hikma is lining up launches of both rituximab and trastuzumab into the region’s oncology arena.
By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.